THE EFFECT OF MIRIKIZUMAB ON FECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PHASE 3 STUDIES OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Britta Siegmund  ¹     Bruce E. Sands  ²     Karen Hamrick Samaan  ³     Xingyuan Li     Nathan Morris     Theresa Hunter Gibble     Isabel Redondo  ⁴     Trevor Lissoos     Geert R. D'Haens  ^5    
1 Charité - Universitätsmedizin Berlin, Berlin, Germany
² Icahn School of Medicine at Mount Sinai, New York, United States
³ Eli Lilly and Company, Indianapolis, United States
⁴ Eli Lilly and Company, Lisbon, Portugal
⁵ Amsterdam University Medical Center, Amsterdam, Netherlands

Session
Investigator studies in IBD II (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)